Macquarie Reaffirms Outperform Rating for Surgery Partners (NASDAQ:SGRY)

Macquarie reaffirmed their outperform rating on shares of Surgery Partners (NASDAQ:SGRY) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $35.00 price objective on the stock.

Several other equities research analysts also recently weighed in on SGRY. Cantor Fitzgerald restated an “overweight” rating and set a $43.00 price target on shares of Surgery Partners in a report on Friday, October 4th. UBS Group started coverage on shares of Surgery Partners in a report on Monday, October 14th. They issued a “buy” rating and a $38.00 target price on the stock. Citigroup decreased their price target on shares of Surgery Partners from $38.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. StockNews.com downgraded shares of Surgery Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $49.00 price objective on shares of Surgery Partners in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.13.

Surgery Partners Trading Down 1.3 %

Shares of SGRY stock opened at $29.32 on Monday. The stock has a market capitalization of $3.73 billion, a P/E ratio of -108.59, a price-to-earnings-growth ratio of 2.27 and a beta of 2.76. Surgery Partners has a fifty-two week low of $22.25 and a fifty-two week high of $36.92. The company has a debt-to-equity ratio of 0.96, a quick ratio of 1.69 and a current ratio of 1.83. The company has a 50 day moving average price of $31.09 and a 200 day moving average price of $28.31.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. The business had revenue of $762.10 million during the quarter, compared to the consensus estimate of $735.94 million. Surgery Partners had a negative net margin of 1.17% and a positive return on equity of 2.96%. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.25 earnings per share. Equities research analysts predict that Surgery Partners will post 0.84 EPS for the current fiscal year.

Institutional Trading of Surgery Partners

A number of hedge funds and other institutional investors have recently made changes to their positions in SGRY. First Eagle Investment Management LLC raised its stake in shares of Surgery Partners by 16.5% during the first quarter. First Eagle Investment Management LLC now owns 339,474 shares of the company’s stock worth $10,127,000 after purchasing an additional 48,100 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Surgery Partners by 33.7% in the 1st quarter. BNP Paribas Financial Markets now owns 421,137 shares of the company’s stock worth $12,563,000 after acquiring an additional 106,054 shares during the period. Bamco Inc. NY boosted its holdings in shares of Surgery Partners by 100.0% in the first quarter. Bamco Inc. NY now owns 90,000 shares of the company’s stock valued at $2,685,000 after acquiring an additional 45,000 shares in the last quarter. Lombard Odier Asset Management Europe Ltd acquired a new position in shares of Surgery Partners during the second quarter worth about $4,163,000. Finally, Rhumbline Advisers raised its holdings in Surgery Partners by 19.6% during the second quarter. Rhumbline Advisers now owns 127,952 shares of the company’s stock worth $3,044,000 after purchasing an additional 20,963 shares in the last quarter.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.